lansbermin-I

Lansbermin-I is an RGD-type disintegrin peptide isolated from the venom of the snake Porthidium lansbergii. It is being investigated as a potential therapeutic for glioblastoma due to its ability to selectively target and inhibit tumor cell viability. The molecule acts by binding with high affinity to the integrin αvβ3 receptor, effectively competing with extracellular matrix proteins like fibronectin for the binding site. This antagonism leads to G1 phase cell cycle arrest and the induction of apoptosis in glioblastoma cells. Preclinical studies have demonstrated that Lansbermin-I exhibits higher cytotoxicity than temozolomide at significantly lower molar concentrations, while maintaining lower toxicity toward non-tumorigenic astrocytes.